Candidate selection and preclinical evaluation culminating in the discovery of Narlaprevir (SCH 900518): A potent, selective and orally efficacious second generation HCV NS3 serine protease inhibitor
Arasappan, A., Bennett, F., Bogen, S.L., Blackman, M., Chen, K., Hendrata, S., Huang, Y., Huelgas, R.M., Nair, L., Padilla, A.I., Pan, W., Pike, R., Pinto, P., Ruan, S., Sannigrahi, M., Velaquez, F., Vibulbhan, B., Wu, W., Yang, W., Saksena, A.K., Girijavallabhan, V., Shih, N.Y., Kong, J., Meng, T., Jin, Y., Wong, J., McNamara, P., Prongay, A., Madison, V., Piwinski, J.J., Cheng, K.C., Morrison, R., Malcolm, B., Tong, X., Ralston, R., Njoroge, F.G.
To be Published